GIST

The FDA has granted breakthrough therapy designation to Pembrolizumab (Keytruda) as a potential therapy for patients with microsatellite instability-high metastatic colorectal cancer.

The FDA has approved MM-398 in combination with 5-fluorouracil and leucovorin as a treatment for patients with metastatic pancreatic cancer.

Hypofractionated radiotherapy can achieve similar cure rates with similar side effects compared with conventional radiotherapy for men with low-risk, early prostate cancer, according to a recent study.

Patients who received hypofractionated radiation therapy did not demonstrate statistically significant differences in long-term outcomes compared with patients who received conventional radiation therapy, according to a study .

Everolimus demonstrated a 52% reduction in the risk of progression or death in patients with lung/gastrointestinal neuroendocrine tumors, improving progression-free survival by 7.1 months compared with placebo.

Hypofractionation, known as delivering higher doses of radiation in fewer fractions, appears to be feasible and non-inferior compared with conventional fractionated radiotherapy.

Flares of bone pain decreased significantly when the oral corticosteroid dexamethasone was added to radiation therapy in patients with metastatic cancer, according to a randomized, placebo-controlled trial.

Coordinating radiation therapy teams and palliative care teams based on patient reported outcomes from University of Virginia Health System improved outpatient symptom management and decreased end-of-life hospitalizations, as well as costs of care for patients with late-stage cancer.

The USPSTF recently posted a draft recommendation statement and draft evidence review on screening for colorectal cancer prompting responses from organizations and industry.

A more than 25-month improvement in overall survival was seen with lyso-thermosensitive liposomal doxorubicin (LTLD; ThermoDox) combined with optimized (?45 minutes dwell time) radiofrequency ablation in patients with hepatocellular carcinoma.

Patients with advanced lung and gastrointestinal neuroendocrine tumors had a 52% reduction in risk of progression or death with everolimus compared with placebo.

The oral nucleoside TAS-102 (Lonsurf) has been approved by the FDA for patients with advanced colorectal cancer (CRC) who are not responding to other treatments.

Researchers from United States and Ireland have formed a partnership to advance nanoparticle-based delivery systems that would not only drive sustained-release of cytotoxic agents, but could improve penetration of these treatments within the tumor and allow them to continue working for days or weeks.

A novel basket trial has reported results on the treatment of vemurafenib in variety of nonmelanoma cancers with BRAF V600 mutation.

Recent therapeutic advances have almost doubled the survival of patients with metastatic pancreatic cancer, and the availability of highly active chemotherapy regimens is making personalized medicine a reality.

Updated findings from the KEYNOTE-012 trial have demonstrated promising antitumor activity with pembrolizumab (Keytruda) in patients with metastatic gastric cancer.

Hand-foot skin reaction represents one of the most troublesome adverse events associated with the multikinase inhibitor regorafenib, yet most treating physicians are unfamiliar with management tactics for this debilitating side effect.

A panel of expert clinical investigators discussed details of several treatments and a dozen patient cases involving gastric, colorectal, and pancreatic cancer at a satellite meeting of the 2015 ASCO GI Cancers Symposium.

In many cases, prostate cancer grows slowly and causes few symptoms; thus, many men remain unaware that they have the disease.

Metastatic disease accounts for the vast majority of cancer-related deaths. Ensuring a definitive diagnosis and the most effective treatment in a timely fashion is essential for extending life expectancy.

Researchers for Caris Life Sciences have used the company's proprietary tumor profiling platform to identify biomarkers in GIST that may be used to identify more effective therapeutic regimens for individuals with TKI-resistant GIST.

A 12-gene test for breast cancer recurrence after ductal carcinoma in situ (DCIS) distinguished high- and intermediate- risk patients from those with a low risk. These results were presented at the 2014 San Antonio Breast Cancer Symposium.

Using more accurately defined data than previous studies, a team of investigators at the UCSD School of Medicine has characterized the epidemiology of GIST.

William D. Tap, MD, discusses the potential to combine KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas.

Tanios Bekaii-Saab, MD, Section Chief, Gastrointestinal Oncology, associate professor, Internal Medicine, Pharmacology, The Ohio State University, discusses an analysis of two targeted drugs for the treatment of patients with colorectal cancer (CRC).